

2013

**University Health Network & Mount Sinai
CARDIOVASCULAR PHARMACOTHERAPY HANDBOOK**

**RESPONSIBILITIES OF THE CARDIOVASCULAR SUBCOMMITTEE
OF THE PHARMACY AND THERAPEUTICS COMMITTEE**

1. The Cardiovascular Subcommittee is responsible for promoting rational use of cardiovascular drugs at University Health Network (UHN) and Mount Sinai Hospital (MSH). The Cardiovascular Subcommittee will make recommendations to the Pharmacy and Therapeutics (P&T) Committee regarding safe, effective and cost-effective use of cardiovascular drugs.
2. More specifically, the Cardiovascular Subcommittee will:
 - Serve in an advisory capacity to the P&T Committee in all matters pertaining to the use of cardiovascular drugs.
 - Evaluate new therapies relevant to patients with cardiovascular disease as part of the hospital's formulary review process, and make recommendations to the P&T Committee regarding their implementation. The evaluation process will include objective assessment of clinical data (both efficacy and safety) and cost impact.
 - Develop guidelines for the appropriate use of cardiovascular drugs.
 - Promote the rational and cost effective use of cardiovascular drugs.
 - Conduct drug utilization evaluation to determine if actual use reflects recommendations.
 - Recommend policies and procedures for prescribing cardiovascular drugs with respect to:
 - current legislation and/or guidelines
 - security and control
 - quality of the drug product
 - any special training requirements in administering drug products
 - any special funding or reimbursement guidelines, as needed.
 - Review requests for non-formulary cardiovascular-related drugs associated with high costs or special administration and/or monitoring requirements.
 - Review requests for restricted cardiovascular-related formulary drugs being prescribed for indications outside accepted standards of practice within the hospital.
 - Review the cardiovascular related drug budgets at UHN and MSH annually, or more frequently, as necessary. Recommend policies or guidelines for the prescribing of cardiovascular-related drugs in order to contain costs within the budget while delivering the highest quality of care for patients with cardiovascular disease.
 - Review and make recommendations involving requests for the intravenous administration of cardiovascular-related drugs (including investigational and special access drugs) by nursing.
3. The Cardiovascular Subcommittee will assist the P&T Committee in the formulation and communication of educational programs designed to meet the needs of the professional staff (physicians, nurses, pharmacists, respiratory therapists, etc.) so that they may have complete and current knowledge on matters related to cardiovascular drugs and cardiovascular drug practices.
4. At the request of the Clinical Operations Committee (COC) and the P&T Committee, the Cardiovascular Subcommittee will review and make recommendations to the P&T Committee concerning cardiovascular-related drug therapy which appears in Preprinted Doctor's Orders, Medical Directives and Delegated Controlled Acts.

January 2011